Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Genomic Health to Market Epic Sciences’ AR-V7 Liquid Biopsy Test

Genomic Health to Market Epic Sciences’ AR-V7 Liquid Biopsy Test

Jul 07, 2016
|
staff reporter

NEW YORK (GenomeWeb) - Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

Genomic Health will also make an equity investment in Epic Sciences, but the companies did not disclose details of that investment or further financial terms of the agreement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Earlier in the US

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

How the Proteins Shape Up

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

Who's to Be First?

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

PNAS Papers on Ovarian Cancer, Retrotransposon Insertions in Cancer, Malaria Mosquitoes

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.

Dec
03
Featured Webinar

Leveraging Multi-Omic Approaches to Understand Disease Stem Cells in Myeloid Malignancies

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

What's Popular?

In Molecular Diagnostics

  1. Grail Inks Deal With UK National Health Service to Offer Cancer Screening Blood Test in 2021

  2. European Consortium Seeks to Develop Liquid Biopsy Test for Prostate, Testicular Cancer

    Premium

  3. Progenity to Raise $100M in Separate Public Stock, Private Senior Notes Offerings

  4. Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

    Premium

  5. Cepheid, Roche Coronavirus Tests Get FDA Emergency Use Authorization

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.